Cancer Genomics Facility (CGF) The Cancer Genomics Facility (formerly a component of the Cancer Biomarkers Facility) performs quantitative sample assessment, comprehensive genotyping, and transcriptome profiling of tumor tissues, cells and related biological fluids (blood, urine, saliva) of clinical relevance. Analysis incorporates optimized hybridization or primer driven assays for genomic capture and interrogation utilizing state of the art PCR, microarray (bead, plate, cartridge) and, since 2012, sequencing (whole genome, exome, custom targeted) technologies.
The Specific Aims of the CGF are to 1) provide ?state of the art? genomic and transcriptomic services, 2) assist with study design and provide consultation services, 3) provide integrated bioinformatics and statistical analysis support, 4) strategically develop and implement advanced technologies, and 5) provide genomics leadership, administrative, and operational excellence. The facility is located adjacent to the UPCI Tissue and Research Pathology Services shared resource to expedite processing of specimens from diverse preparations ranging from whole mounted tissues (fresh, flash frozen, formalin fixed) to individual tumor stem cells. Protocols routinely incorporate manual and laser capture microdissection to mitigate effects of tumor heterogeneity. Novel methods have been developed to capture and amplify limiting amounts of DNA and RNA (<1ng) from archival (>10 years old) formalin fixed, paraffin embedded specimens. The CGF has generated an extensive reference database of single nucleotide polymorphisms and genomic sequence (70 samples) from ?normal? tissues for patient samples lacking matched germline specimens e.g. to serve as a gene copy number control. CGF collaborates closely with TARPS and CBS to ensure that UPCI investigators have benefit from optimized workflows. The facility routinely provides services to researchers from UPCI Programs, spanning basic, population science, and translational drug discovery and disease-site programs as well as each of the 3.5 SPOREs housed at UPCI. The CGF is also an integral component of the UPCI high- risk, high-reward initiative supporting development of early stage investigators and promoting new research pathways for established investigators. During the current project period investigators in nine UPCI Research Programs used the CGF.
|Correa, Andres F; Toussi, Amir; Amin, Milon et al. (2018) Small Renal Masses in Close Proximity to the Collecting System and Renal Sinus Are Enriched for Malignancy and High Fuhrman Grade and Should Be Considered for Early Intervention. Clin Genitourin Cancer 16:e729-e733|
|Wang, Yi-Jun; Fletcher, Rochelle; Yu, Jian et al. (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194-203|
|Bakkenist, Christopher J; Lee, James J; Schmitz, John C (2018) ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. Clin Colorectal Cancer 17:255-257|
|Low, Carissa A; Bovbjerg, Dana H; Ahrendt, Steven et al. (2018) Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission. Ann Behav Med 52:88-92|
|Tasdemir, Nilgun; Bossart, Emily A; Li, Zheqi et al. (2018) Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res 78:6209-6222|
|Mazharuddin, Samir; Chattopadhyay, Anuja; Levy, Moshe Y et al. (2018) IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid. Leuk Lymphoma 59:2246-2249|
|Basudan, Ahmed; Priedigkeit, Nolan; Hartmaier, Ryan J et al. (2018) Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Mol Cancer Res :|
|Beumer, Jan H; Chu, Edward; Allegra, Carmen et al. (2018) Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther :|
|Song, Xinxin; Zhu, Shan; Chen, Pan et al. (2018) AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol 28:2388-2399.e5|
|Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196|
Showing the most recent 10 out of 1187 publications